


CLAIMS

1. A crystalline form 2,2-difluoro-*N*-[(1*R*,2*S*)-3-methyl-1-{ [1-(1-methyl-6-oxo-1,6-dihydropyridin-3 -yl)- 1 *H*-indazol-5-yl]oxy}-1-phenylbutan-2-yl]propanamide :



that has an X-ray powder diffraction pattern with at least one specific peak at 2θ about = 7.3, 8.7, 12.5 and/or 15.3° when measured using CuK α radiation.

2. A compound according to claim 1, characterised in that it has an X-ray powder diffraction pattern with at least 3 specific peaks at 2θ about = 7.3, 8.7, 12.5, 15.3 and/or 19.0° when measured using CuK α radiation.

3. A compound according to claim 1, characterised in that it has an X-ray powder diffraction pattern with specific peaks at 2θ about = 7.3, 8.7, 12.5, 19.4 and 23.6° when measured using CuK α radiation.

4. A compound according to claim 1, characterised in that it has X-ray powder diffraction pattern with specific peaks at 2θ about = 7.3, 8.7, 11.4, 12.5, 14.5, 15.3, 17.6, 19.4, 23.6 and 25.7° when measured using CuK α radiation.

5. A compound according to claim 1, characterised in that it has an X-ray powder diffraction pattern substantially as shown in Figure 1 , when measured using CuK α radiation.

6. A pharmaceutical composition comprising a compound as claimed in claim 1 in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

7. The compound according to claim 1 for use in therapy
8. The compound according to claim 1 for use as a medicament.
9. The compound according to claim 1 for use in treating asthma.
10. The compound according to claim 1 for use in treating rheumatoid arthritis.
11. Use of a compound as claimed in claim 1 in the manufacture of a medicament for the treatment of asthma, wherein a therapeutically effective amount of the medicament is to be administered to a patient.
12. Use of a compound as claimed in claim 1 in the manufacture of a medicament for the treatment of rheumatoid arthritis, wherein a therapeutically effective amount of the medicament is to be administered to a patient.